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Abstract
Gene expression profiling was performed on laser captured breast
stroma and epithelium obtained from 14 breast cancer patients. As
with breast epithelium, of the stromal gene expression changes
observed between normal tissue and invasive ductal carcinoma,
greater than 90% occurred early, at the normal to ductal carcinoma
in situ transition. Only 10% of stromal and 0% of epithelial genes
were differentially regulated between non-invasive ductal carci-
noma in situ and invasive disease. These data suggest that the
majority of gene expression changes required for transformation
occur early, prior to histological evidence of an invasive phenotype,
the stroma cooperates closely with epithelium in this
transformation, and for acquisition of the invasive phenotype, the
stroma is dominant over the epithelium.
In the previous issue of Breast Cancer Research Xiao-Jun Ma
and colleagues of the Dennis C Sgroi laboratory report on a
comparative analysis of global gene expression in the micro-
environment of ductal carcinoma as it relates to the acquisition
of invasiveness [1]. The authors utilize an approach that
significantly reduces confounding signals in the data due to
inter-patient variability by performing laser capture on breast
tissue from 14 breast cancer patients with matched normal
and tumor samples. The majority of the cohort was pre-
menopausal (mean age 41 years), with estrogen receptor
positive tumors (78%) and ipsilateral nodal involvement
(78%). Thus, this study focuses on young women’s breast
cancer, an important but understudied subset that is asso-
ciated with poor prognosis [2,3].
Previous work from this group showed that gene expression
changes in epithelium occur prior to local invasion, as early as
atypical ductal hyperplasia [2]. Surprisingly, no major
changes in epithelial gene expression were identified
between  in situ and invasive cancers. The authors now
confirm these earlier results and demonstrate that, like the
epithelium, tumor stroma undergoes dramatic gene expres-
sion alterations early, at the transition from normal to ductal
carcinoma in situ (DCIS). Over 3,500 stromal genes were
identified to be differentially regulated in DCIS compared to
normal, whereas only 305 stromal genes were differentially
regulated with the transition to invasion. These observations
highlight early events that occur prior to histological evidence
of local invasion, and the co-dependency between epithelial
cells and the stroma, in regulating tumor progression.
Another important contribution of this work is the identifi-
cation of a stromal gene signature that marks the transition to
local invasion. While only three epithelial genes were
identified as differentially regulated between DCIS and locally
invasive disease, 76 stromal genes were upregulated and
229 downregulated in invasive cancers compared to DCIS.
These new data further challenge the epithelial cell-centric,
multi-hit model of metastasis by demonstrating that it is a
stromal gene signature, not an epithelial signature, that
distinguishes pre-invasive from invasive cancer. In 2002 van ’t
Veer and colleagues [3] demonstrated the power of global
gene profiling by showing for the first time that expression
signatures of the primary tumor could predict risk of
metastasis with high accuracy. The van ’t Veer study
fundamentally undermined the prevailing hypothesis that
metastasis is solely mediated by the acquisition of rare and
rate limiting mutations within a minority of tumor cells [4].
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Subsequent studies have demonstrated that having a poor
prognosis gene signature is not sufficient for metastasis, as
many cancers with such signatures do not metastasize [5].
These studies and others helped re-awaken interest in the
role of the tumor microenvironment in orchestrating the
metastatic switch [6].
The paper by Xiao-Jun Ma and colleagues adds to an
impressive list of recent gene expression studies designed to
investigate the role of the tumor microenvironment in breast
cancer [7-10]. Prior to the reporting of these gene profiling
studies, a histologically defined fibrotic response referred to
as tumor desmoplasia had been correlated with poor prog-
nosis [11,12]. In the study by Xiao-Jun Ma and colleagues,
the short chain collagen types X and VIII and fibronectin were
upregulated four- to six-fold in stroma surrounding DCIS
compared to adjacent normal stroma, implicating these
extracellular matrix (ECM) proteins in cancer progression.
Pre-clinical studies strongly support the hypothesis that
collagens and fibronectin directly promote metastatic
phenotypes in cancer cells. For example, fibronectin signaling
through β1 integrin was recently found to cause loss of tumor
cell quiescence via phosphorylation of myosin light chain and
cytoskeletal reorganization [13]. Thus, it was somewhat
surprising when two independent studies, utilizing gene
profiles identified from very disparate tissue samples,
reported that ECM proteins associated with the fibrotic
response, including fibronectin, collagens I, III, and VI,
biglycan, fibulin 2, SPARC, and connective tissue growth
factor were associated with improved survival [10,14].
Resolution of these apparent contradictory observations will
require significant advancement in the ECM field, including
additional functional characterization of the ECM
constituents, such as the 26 genetically distinct collagen
types identified to date. Improvements in our understanding
of matrix assembly, cross-linking, signaling and turnover will
be required as well.
Insight into why a tumor fibrotic ECM signature could have
dual effects on survival prognosis may be provided by the list
of stromal genes upregulated at the DCIS to invasion
transition, as reported by Xiao-Jun Ma and colleagues. This
transition was accompanied by increased stromal expression
of the matrix metalloproteinases MMP-2, MMP-11 and MMP-
14. Further, these authors found that stroma of invasive
tumors was associated with a strong immune response
signature, consistent with a large body of literature revealing
multiple mechanisms by which immune cells positively
regulate tumor progression [15]. Given that fragments of
ECM proteins are key attractants and activators of immune
cells under pathological conditions, differential proteolysis of
tumor ECM and subsequent recruitment of immune cells may
discriminate between tumor fibrosis associated with good
prognosis from poor prognosis. Global gene expression
profiling studies have helped formulate these exciting
hypotheses and will no doubt continue to challenge our
assumptions about breast cancer initiation, invasion and
metastasis, permitting us to make inroads into this disease in
ways previously unimagined.
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